Enzyme Replacement Therapy
"Enzyme Replacement Therapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Therapeutic replacement or supplementation of defective or missing enzymes to alleviate the effects of enzyme deficiency (e.g., GLUCOSYLCERAMIDASE replacement for GAUCHER DISEASE).
| Descriptor ID |
D056947
|
| MeSH Number(s) |
E02.319.353.500
|
| Concept/Terms |
Enzyme Replacement Therapy- Enzyme Replacement Therapy
- Enzyme Replacement Therapies
- Replacement Therapies, Enzyme
- Replacement Therapy, Enzyme
- Therapies, Enzyme Replacement
- Therapy, Enzyme Replacement
|
Below are MeSH descriptors whose meaning is more general than "Enzyme Replacement Therapy".
Below are MeSH descriptors whose meaning is more specific than "Enzyme Replacement Therapy".
This graph shows the total number of publications written about "Enzyme Replacement Therapy" by people in this website by year, and whether "Enzyme Replacement Therapy" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 2 | 3 | 5 |
| 2018 | 3 | 6 | 9 |
| 2019 | 3 | 0 | 3 |
| 2020 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Enzyme Replacement Therapy" by people in Profiles.
-
Challenges in Chronic Genetic Disorders: Lessons From the COVID-19 Pandemic. Indian Pediatr. 2021 Apr 15; 58(4):391-392.
-
Invisible burden of COVID-19: enzyme replacement therapy disruptions. J Pediatr Endocrinol Metab. 2021 May 26; 34(5):539-545.
-
The impact of interrupting enzyme replacement therapy in late-onset Pompe disease. J Neurol. 2021 Aug; 268(8):2943-2950.
-
Gaucher disease in the COVID-19 pandemic environment: The good, the bad and the unknown. Mol Genet Metab. 2021 04; 132(4):213-214.
-
When Frequent (Pandemic) Occurs in a Non-Frequent Disease: COVID-19 and Fabry Disease: Report of Two Cases. Jpn J Infect Dis. 2021 May 24; 74(3):228-232.
-
Direct and indirect effects of the SARS-CoV-2 pandemic on Gaucher Disease patients in Spain: Time to reconsider home-based therapies? Blood Cells Mol Dis. 2020 11; 85:102478.
-
Fabry disease during the COVID-19 pandemic. Why and how treatment should be continued. Mol Genet Metab. 2020 08; 130(4):227-229.
-
COVID-19 and relative angiotensin-converting enzyme 2 deficiency: role in disease severity and therapeutic response. Open Heart. 2020 06; 7(1).
-
Impact of COVID-19 related healthcare crisis on treatments for patients with lysosomal storage disorders, the first Italian experience. Mol Genet Metab. 2020 07; 130(3):170-171.
-
Enzyme replacement therapy with recombinant pro-CTSD (cathepsin D) corrects defective proteolysis and autophagy in neuronal ceroid lipofuscinosis. Autophagy. 2020 05; 16(5):811-825.